Tenaya reports Q2 2026 results with new TN-201, TN-401 data and Alnylam upfront payment
Interim gene therapy data and a $10 million Alnylam payment accompany fourth-quarter 2026 regulatory update plans for both lead programs.
SEC filing
Latest
1 story